Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, which are in Phase I and IND-enabling respectively. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics Inc.

The latest update is out from Kymera Therapeutics ( ($KYMR) ). On March 25, 2026, Kymera Therapeutics’ board amended its bylaws to make U.S. federa...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KYMR	$85.50	-2.12%	246.58K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KYMR	$85.50	-2.1%	246.58K
3
4
5
6

KYMR

KYMR

Get Kymera Therapeutics Inc. Data in Excel

Get Kymera Therapeutics Inc. Data in Excel